Program
Digoxin
Also written as “digoxin”, “ZT002 injection, rosuvastatin, digoxin” and “Digoxin (0.25mg)”.
Its studies are mostly in Obesity · Neoplasms · Thalassemia · Carcinoma, Non-Small-Cell Lung · Liver Cirrhosis, led by 25 companies.
Drug pageDigoxin: every studyMany companies study it; this page follows only the 43 they lead. All 87 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheimits history only | 90 open or running | phase 1since Jun 1, 2010 | Jun 1, 2010 | none ahead |
| AstraZenecaits history only | 30 open or running | phase 1since Jul 8, 2008 | Jul 8, 2008 | none ahead |
| Bristol-Myers Squibbits history only | 30 open or running | phase 1since Oct 9, 2014 | Oct 9, 2014 | none ahead |
| Astellas Pharmaits history only | 20 open or running | phase 1since Apr 29, 2014 | Apr 29, 2014 | none ahead |
| GlaxoSmithKlineits history only | 20 open or running | phase 1since Mar 28, 2008 | Mar 28, 2008 | none ahead |
| Hoffmann-La Rocheits history only | 20 open or running | phase 1since Jan 9, 2013 | Jan 9, 2013 | none ahead |
| Johnson & Johnsonits history only | 20 open or running | phase 1since Jan 20, 2011 | Jan 20, 2011 | none ahead |
| Merckits history only | 20 open or running | phase 1since Aug 26, 2024 | Aug 26, 2024 | none ahead |
| Sanofiits history only | 20 open or running | phase 1since May 19, 2011 | May 19, 2011 | none ahead |
| AbbVieits history only | 10 open or running | phase 1since Feb 3, 2016 | Feb 3, 2016 | none ahead |
| Beijing QL Biopharmaceuticalits history only | 11 open or running | phase 1since Apr 20, 2026 | Apr 20, 2026 | Dec 5, 2026phase 1 · NCT07550816 |
| Biogenits history only | 10 open or running | phase 1since May 11, 2012 | May 11, 2012 | none ahead |
| CMP Developmentits history only | 10 open or running | phase 1since Feb 16, 2019 | Feb 16, 2019 | none ahead |
| CSLits history only | 10 open or running | phase 1since Nov 16, 2011 | Nov 16, 2011 | none ahead |
| Daiichi Sankyoits history only | 10 open or running | phase 1since Jan 4, 2012 | Jan 4, 2012 | none ahead |
| Eisaiits history only | 10 open or running | phase 1since Jan 23, 2014 | Jan 23, 2014 | none ahead |
| Eli Lillyits history only | 10 open or running | phase 1since Dec 16, 2023 | Dec 16, 2023 | none ahead |
| Jiangsu HengRui Medicineits history only | 10 open or running | phase 1since Mar 17, 2020 | Mar 17, 2020 | none ahead |
| Maruhoits history only | 10 open or running | phase 2since Dec 19, 2014 | Dec 19, 2014 | none ahead |
| Merck KGaA, Darmstadt, Germanyits history only | 10 open or running | phase 1since Sep 23, 2021 | Sep 23, 2021 | none ahead |
| Novo Nordiskits history only | 10 open or running | phase 1since Feb 3, 2025 | Feb 3, 2025 | none ahead |
| Pfizerits history only | 10 open or running | phase 1since Jan 27, 2009 | Jan 27, 2009 | none ahead |
| pharmaand | 10 open or running | phase 1since Mar 30, 2016 | Mar 30, 2016 | none ahead |
| Puma Biotechnologyits history only | 10 open or running | phase 1since Mar 11, 2009 | Mar 11, 2009 | none ahead |
| Takedaits history only | 10 open or running | phase 1since Apr 20, 2016 | Apr 20, 2016 | none ahead |
Also a collaborator on its studies: Parexel, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene and Medpace.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of pharmaand only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 30, 2016First study: phase 1 study in NeoplasmsFirst studyNCT02740712 · 17 enrolled · Poland
TargetBeta
“Sodium/potassium-transporting ATPase inhibitor”ChEMBL 37, by rule
Other programs on the same 8 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Istaroximerule | windtree-therapeutics | phase 3 | 8 |
Studies
The one study pharmaand leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02740712Neoplasms · Poland | 1 | Completed | Mar 2017 | 17 |
How it is read
Names in the registry
- “Digoxin”, 33 entries
- “digoxin”, 6 entries
- “ZT002 injection, rosuvastatin, digoxin”, 1 entry
- “Digoxin (0.25mg)”, 1 entry
- “Lenoxin®”, 1 entry
Conditions, from the studies’ own filings
- Obesity, 2 studies
- Neoplasms, 2 studies
- Thalassemia, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Liver Cirrhosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.